Damali N. Martin, Ph.D., M.P.H.
Program Director, Host Susceptibility Factors Branch
Contact Information
Epidemiology and Genetics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
6130 Executive Blvd., Rm. 5120, MSC 7393
Bethesda, MD 20892-7393
(For express delivery, use Rockville, MD 20852)
telephone: (301) 451-1956
fax: (301) 402-4279
e-mail: mailto:martinda@mail.nih.gov
Interest Areas
Health disparities research, specifically for breast and prostate cancer and whether tumor biology contributes to differences in survival between African-American and Caucasian breast and prostate cancer patients.
Degrees
Ph.D. - Cell biology and Molecular Genetics
University of Maryland, College Park
M.P.H. - Epidemiology and Biostatistics
The Johns Hopkins Bloomberg School of Public Health
B.S. - Cell Biology and Molecular Genetics
University of Maryland, College Park
Biography
Dr. Martin is a Program Director in the Epidemiology and Genetics Research Program's (EGRP) Host Susceptibility Factors Branch (HSFB). Her responsibilities include management of a portfolio of grants related to factors that influence personal susceptibility to cancer. She is also the EGRP contact for the Genes, Environment, and Melanoma (GEM) Consortium
and a Steering Committee member for the Division of Cancer Control and Population Sciences (DCCPS)-funded Centers for Population Health and Health Disparities.
Before joining EGRP in 2008, Dr. Martin was a Cancer Prevention Fellow at NCI and worked in the Breast and Prostate Study Group in the Laboratory of Human Carcinogenesis, Center for Cancer Research. Her intramural work involved research on the association of DNA polymorphisms and breast cancer risk, as well as other epidemiological studies with a focus on molecular epidemiology and health disparities.
In addition to her responsibilities as a Program Director, Dr. Martin collaborates with her former Laboratory of Human Carcinogenesis to continue to examine biological determinants of disparities in survival from prostate cancer.
